The UK’s competition watchdog has provisionally found three drug firms signed an illegal agreement, resulting in huge price hikes for an essential medicine used by the NHS.
The controversy over Novartis’ ultra-pricey gene therapy Zolgensma has intensified after it allegedly refused to supply the one-off therapy to a sick toddler in Belgium on compassionate gro
